BioCentury
ARTICLE | Clinical News

XTL Phase II HBV interim results

December 10, 2001 8:00 AM UTC

XTL Biopharmaceuticals (LSE:XTL) said in an ongoing 60-patient, placebo-controlled Phase IIa study of XTL-001 plus lamivudine, hepatitis B virus (HBV) DNA levels were lowered to an undetectable level ...